To further verify our hypothesis, we used the p-ERK1/2 inhibitor SCH772984 (HY-50846, MCE, USA) to pharmacologically block the ERK1/2 pathway and investigated the angiogenesis, migration and invasion of ICC cells. This evidence concerns the gene MAPK3 and intrahepatic cholangiocarcinoma.